SML3117

N-Desethyl sunitinib hydrochloride

≥98% (HPLC)

• 同義詞: 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylaminoethyl)amide hydrochloride, N-Desethylsunitinib hydrochloride, N-[2-(Ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide hydrochloride, SU 12662 hydrochloride, SU12662 hydrochloride
• 經驗公式（希爾表示法）: C₂₀H₂₃FN₄O₂ · xHCl
• CAS號碼: 356068-97-8
• 分子量：: 370.42 (free base basis)
• MDL號碼: MFCD18252482
• 分類程式碼代碼: 12352200
• NACRES: NA.77

屬性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 儲存條件: desiccated
• 顏色: white to beige
• 溶解度: DMSO: 2 mg/mL, clear (warmed)
• 儲存溫度: 2-8°C
• InChI: 1S/C20H23FN4O2/c1-4-22-7-8-23-20(27)18-11(2)17(24-12(18)3)10-15-14-9-13(21)5-6-16(14)25-19(15)26/h5-6,9-10,22,24H,4,7-8H2,1-3H3,(H,23,27)(H,25,26)/b15-10-
• InChI 密鑰: LIZNIAKSBJKPQC-GDNBJRDFSA-N

描述

生化／生理作用

N-Desethyl sunitinib is a multi-target tyrosine kinase inhibitor that is a major active metabolite of an anticancer drug sunitinib. N-Desethyl sunitinib has a similar kinase inhibitory effect as sunitinib. In patients, plasma sunitinib and N-desethyl sunitinib accounts for 42% and 24%, respectively. Thus N-desethyl sunitinib accounts for one third of the therapeutic effect of oral sunitinib.

安全資訊

• 象形圖: GHS08,GHS09
• 訊號詞: Warning
• 危險聲明: H361d,H373,H410
• 防範說明: P202 - P260 - P273 - P280 - P308 + P313 - P391
• 危險分類: Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 2 - STOT RE 2
• 標靶器官: blood vessel,Bone marrow
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable